Valuation: Emergent BioSolutions Inc.

Market Cap 30Cr 27Cr 25Cr 23Cr 42Cr 2.81TCr 44Cr 299.74Cr 118.85Cr 1.5TCr 111.72Cr 109.35Cr 4.76TCr P/E 2026 *
-1.27x
P/E 2027 * 81.1x
Enterprise Value 67Cr 61Cr 56Cr 51Cr 95Cr 6.3TCr 99Cr 672.45Cr 266.64Cr 3.36TCr 250.63Cr 245.31Cr 11TCr EV / Sales 2026 *
1.03x
EV / Sales 2027 * 0.86x
Free-Float
79.3%
Yield 2026 *
-
Yield 2027 * -
1 week-4.46%
Current month-14.98%
1 month-19.36%
3 months+26.14%
6 months-27.08%
Current year-53.16%
1 week 5.76
Extreme 5.76
6.13
1 month 5.51
Extreme 5.51
7.3
Current year 4.36
Extreme 4.36
14.06
1 year 4.36
Extreme 4.36
14.06
3 years 1.42
Extreme 1.42
15.1
5 years 1.42
Extreme 1.42
52.28
10 years 1.42
Extreme 1.42
137.61
Manager TitleAgeSince
Chief Executive Officer 70 21/02/2024
Director of Finance/CFO 62 26/03/2018
Compliance Officer 55 01/03/2020
Director TitleAgeSince
Chairman 82 01/04/2022
Director/Board Member 70 01/01/2005
Director/Board Member 77 01/10/2016
Date Insider Type Main position Quantity % Market Cap. Importance
07/10/26 Sell

Director

-17,800 0.0347%
01/10/26 Sell

Executive/Senior Manager

-3,000 0.0059%
05/08/26 Other

Executive/Senior Manager

4,55,311 0.8824%
Change 5-day change 1-year change 3-year change Capi.($)
+0.86%-4.46%-42.73%+161.99% 30Cr
+1.63%+6.61%+40.79%+145.27% 1,28600Cr
+0.89%+3.45%+45.84%+92.04% 69TCr
+1.65%+1.28%+26.97%+114.41% 52TCr
+1.33%+2.22%+42.76%+73.11% 39TCr
+0.47%+0.70%+59.02%+45.79% 36TCr
+1.75%+2.07%+28.78%+63.67% 30TCr
+1.19%+0.55%+4.06%+39.13% 29TCr
+1.13%+1.14%+38.29%+70.56% 25TCr
+1.56%+0.71%+34.44%+123.99% 21TCr
Average +1.02%+1.42%+27.82%+92.99% 43TCr
Weighted average by Cap. +1.21%+3.26%+37.89%+99.84%

Financials

2026 *2027 *
Net sales 65Cr 59Cr 54Cr 49Cr 92Cr 6.1TCr 95Cr 651.24Cr 258.23Cr 3.26TCr 242.72Cr 237.57Cr 10TCr 70Cr 64Cr 59Cr 53Cr 100.24Cr 6.63TCr 103.77Cr 708.17Cr 280.8Cr 3.54TCr 263.94Cr 258.34Cr 11TCr
Net income -24Cr -22Cr -20Cr -18Cr -34Cr -2.24TCr -35Cr -238.96Cr -95Cr -1.2TCr -89Cr -87Cr -3.79TCr 38.26L 34.67L 32.07L 28.93L 54.53L 36Cr 56.45L 3.85Cr 1.53Cr 19Cr 1.44Cr 1.41Cr 61Cr
Net Debt 37Cr 34Cr 31Cr 28Cr 53Cr 3.49TCr 55Cr 372.71Cr 147.79Cr 1.86TCr 138.91Cr 135.96Cr 5.92TCr 31Cr 28Cr 26Cr 23Cr 44Cr 2.91TCr 46Cr 310.98Cr 123.31Cr 1.56TCr 115.9Cr 113.45Cr 4.94TCr
Projected Income Statement - Annual - Emergent BioSolutions Inc.
Logo Emergent BioSolutions Inc.
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Employees
900
Date Price Change Volume
14/26/14 $5.790 -1.70% 7,87,177
12/26/12 $5.890 -2.48% 10,03,009
11/26/11 $6.040 -0.17% 5,16,260
10/26/10 $6.050 -0.82% 6,54,434
09/26/09 $6.100 +0.66% 8,46,870
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Emergent BioSolutions Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
5.790USD
Average target price
10.00USD
Spread / Average Target
+72.71%